GlassScriptPhysician profile
Jeremiah A Bartley
NPI 1548341415
$15,023.56
in general payments reported to CMS, 2019-2025
55 companies · $2,292 in 2025
The $2,292 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $1,048 · 2021: $2,803 · 2022: $2,109 · 2023: $2,471 · 2024: $2,089 · 2025: $2,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,759 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,758.91 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,165.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $2,552.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,118.51 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $981.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $728.26 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $664.92 | 2019-2022 | |
| Lilly USA, LLC | $610.73 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astellas Pharma US INC | $583.58 | 2019-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $577.70 | 2021 | |
| Esperion Therapeutics, INC. | $484.67 | 2020-2021 | |
| Madrigal Pharmaceuticals | $441.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $305.32 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.51 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.12 | 2024-2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Bartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.